The Effect of GLP-1 on Glucose Uptake in the Brain and Heart in Healthy Men During Hypoglycemia
NCT00418288 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10
Last updated 2008-06-10
Summary
Type 2 diabetes mellitus, T2D is a disease characterized by an immense growing prevalence world wide with an increased risk of myocardial infarction and stroke. GLP-1 has convincing effects on the high glucose levels in type 2 diabetic patients and is well tolerated. New animal studies indicate a protective effect of GLP-1 in the brain and the heart. The mechanism behind this is yet not known.
The study hypothesis is that during hypoglycaemia GLP-1 will stimulate glucose-uptake in the brain and heart independent of insulin and thereby exert protective effects in the brain.
Conditions
Interventions
- DRUG
-
glucagon-like-peptide-1
intravenous infusion of 1.2pmol/kg/min for 7 hours
- DRUG
-
intravenous infusion of 1.2pmol/kg/min
Sponsors & Collaborators
-
University of Aarhus
lead OTHER
Principal Investigators
-
Ole E Schmitz, MD, DSc · Department of pharmacology, Aarhus university
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 20 Years
- Max Age
- 50 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2007-01-31
- Primary Completion
- 2007-10-31
- Completion
- 2008-02-29
Countries
- Denmark
Study Locations
More Related Trials
-
Glucagon-Like Peptide-1 (GLP-1) Suppression of Alpha Cell Secretion in Type 2 Diabetes Mellitus (T2DM)
NCT00862589 ·Status: COMPLETED ·Phase: NA
-
Influence of Glucagon Inhibition in Relation to the Anti-Diabetic Effect of Glucagon-Like Peptide-1 (GLP-1) in Patients With Type 2 Diabetes Mellitus
NCT00655603 ·Status: UNKNOWN ·Phase: NA
-
Effect of GLP1 Receptor Agonist on Brain Insulin Responsiveness
NCT06487832 ·Status: RECRUITING ·Phase: NA
-
Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 Diabetes
NCT00993720 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Endothelial and Metabolic Effects of Glucagon-like Peptide-1 (GLP-1) in Coronary Circulation in Patients With Type 2 Diabetes Mellitus
NCT00923962 ·Status: COMPLETED ·Phase: NA
-
The Effect of GLP-1 on the Inhibition of Glucagon Secretion
NCT01507597 ·Status: COMPLETED ·Phase: NA
-
Effect of 48 Hours of Treatment With the Natural Peptide-Hormone GLP-1 in Patients With Chronic Heart Failure
NCT00264199 ·Status: COMPLETED ·Phase: NA
-
Glucose-dependent Insulinotropic Polypeptide as a Safeguard Against Hypoglycemia in Patients With Type 1 Diabetes
NCT03556098 ·Status: COMPLETED ·Phase: NA
-
Effects of Glucagon Like Peptide-1 on Haemodynamic Parameters
NCT02490176 ·Status: UNKNOWN ·Phase: NA
-
Acute Effects of GLP-1 on Renal Hemodynamics
NCT04337268 ·Status: COMPLETED ·Phase: NA
-
Glucagon-like Peptide-1 in Type 1 Diabetes
NCT04355832 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors
NCT02792400 ·Status: COMPLETED ·Phase: NA
-
The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET
NCT00747968 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Effect of GLP-1 on Microvascular Insulin Responses in Type 1 Diabetes
NCT04133922 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
Near Normalisation of BG Improves the Potentiating Effect of GLP-1
NCT00612625 ·Status: COMPLETED ·Phase: NA
-
The Effect of GLP-1 on Postprandial Glucagon Secretion Independent of The Gastric Emptying Rate
NCT02584582 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
The Role of Glucose-Dependent Insulinotropic Polypeptide in the Pathological Glucose Homeostasis Of Type 1 Diabetes
NCT03734718 ·Status: COMPLETED ·Phase: NA
-
Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin
NCT04034524 ·Status: UNKNOWN
-
Effects of Oral GLP-1 on Glucose Homeostasis and Appetite Profile in Healthy Male Subjects
NCT00822003 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Development of Agents to Diminish the Risk of Hypoglycemia-induced Brain Injury in Type 1 Diabetes
NCT03356457 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
GLP-2 (Glucagonlike Peptide-2) and Blood Flow
NCT00540215 ·Status: COMPLETED ·Phase: NA
-
GLP-1 Analogue Treatment in Uncontrolled Type 1 Diabetic Patients
NCT01592279 ·Status: UNKNOWN ·Phase: PHASE4
-
The Ameliorative Effects of GLP-1RA on Diabetic Cardiac Autonomatic Neuropathy
NCT06461377 ·Status: RECRUITING ·Phase: PHASE4
-
Is Glucagon-like Peptide-1 Insufficiency a Residual Risk in Coronary Artery Disease?
NCT02280837 ·Status: COMPLETED
-
Effect of GIP After a Meal in Patients With Type 2 Diabetes
NCT03702660 ·Status: COMPLETED ·Phase: NA